company background image
0A4C logo

Altimmune LSE:0A4C Stock Report

Last Price

US$6.74

Market Cap

US$479.0m

7D

-0.7%

1Y

144.8%

Updated

02 Nov, 2024

Data

Company Financials +

Altimmune, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Altimmune
Historical stock prices
Current Share PriceUS$6.74
52 Week HighUS$14.82
52 Week LowUS$2.35
Beta0.064
11 Month Change10.48%
3 Month Change15.15%
1 Year Change144.83%
33 Year Change-37.68%
5 Year Changen/a
Change since IPO-49.33%

Recent News & Updates

Recent updates

Shareholder Returns

0A4CGB BiotechsGB Market
7D-0.7%0.3%-1.1%
1Y144.8%-12.7%10.2%

Return vs Industry: 0A4C exceeded the UK Biotechs industry which returned -12.7% over the past year.

Return vs Market: 0A4C exceeded the UK Market which returned 10.2% over the past year.

Price Volatility

Is 0A4C's price volatile compared to industry and market?
0A4C volatility
0A4C Average Weekly Movement10.4%
Biotechs Industry Average Movement8.3%
Market Average Movement4.7%
10% most volatile stocks in GB Market9.4%
10% least volatile stocks in GB Market2.6%

Stable Share Price: 0A4C's share price has been volatile over the past 3 months compared to the UK market.

Volatility Over Time: 0A4C's weekly volatility has decreased from 16% to 10% over the past year, but is still higher than 75% of UK stocks.

About the Company

FoundedEmployeesCEOWebsite
199759Vipin Gargaltimmune.com

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company’s lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus.

Altimmune, Inc. Fundamentals Summary

How do Altimmune's earnings and revenue compare to its market cap?
0A4C fundamental statistics
Market capUS$479.02m
Earnings (TTM)-US$101.35m
Revenue (TTM)US$409.00k

1,171x

P/S Ratio

-4.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0A4C income statement (TTM)
RevenueUS$409.00k
Cost of RevenueUS$77.94m
Gross Profit-US$77.53m
Other ExpensesUS$23.82m
Earnings-US$101.35m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-1.43
Gross Margin-18,955.99%
Net Profit Margin-24,778.97%
Debt/Equity Ratio0%

How did 0A4C perform over the long term?

See historical performance and comparison